title: Effects of repeated low-dose exposure of the nerve agent VX on monoamine levels in different brain structures in mice.
abstract: In a previous report, alterations of the serotonin metabolism were previously reported in mice intoxicated with repeated low doses of soman. In order to better understand the effects induced by repeated low-dose exposure to organophosphorus compounds on physiological and behavioural functions, the levels of endogenous monoamines (serotonin and dopamine) in different brain areas in mice intoxicated with sublethal dose of (O-ethyl-S-[2(di-isopropylamino) ethyl] methyl phosphonothioate) (VX) were analysed by HPLC method with electrochemical detection. Animals were injected once a day for three consecutive days with 0.10 LD50 of VX (5 μg/kg, i.p). Neither severe signs of cholinergic toxicity nor pathological changes in brain tissue of exposed animals were observed. Cholinesterase (ChE) activity was only inhibited in plasma (a maximum of 30% inhibition 24 h after the last injection of VX), but remained unchanged in the brain. Serotonin and dopamine (DA) metabolism appeared significantly modified. During the entire period of investigation, at least one of the three parameters investigated (i.e. DA and DOPAC levels and DOPAC/DA ratio) was modified. During the toxic challenge, an increase of the serotonin metabolism was noted in hippocampus (HPC), hypothalamus/thalamus, pons medulla and cerebellum (CER). This increase was maintained 4 weeks after exposure in HPC, pons medulla and CER whereas a decrease in cortex 3 weeks after the toxic challenge was observed. The lack of correlation between brain ChE activity and neurochemical outcomes points out to independent mechanisms. The involvement in possibly long-lasting behavioural disorders is discussed.
authors.affiliation: DGA Maîtrise NRBC (Defence Research Center), Le Bouchet, BP N°3, 91710, Vert-Le-Petit, France, sebastien.graziani@intradef.gouv.fr.
authors.forename: S
authors.initials: S
authors.lastname: Graziani
authors.forename: D
authors.initials: D
authors.lastname: Christin
authors.forename: S
authors.initials: S
authors.lastname: Daulon
authors.forename: P
authors.initials: P
authors.lastname: Breton
authors.forename: N
authors.initials: N
authors.lastname: Perrier
authors.forename: L
authors.initials: L
authors.lastname: Taysse
mesh_terms: D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D000818:Animals; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D002800:Cholinesterase Inhibitors / Q000494:pharmacology; D002802:Cholinesterases / Q000097:blood; D004298:Dopamine / Q000378:metabolism*; D008297:Male; D008807:Mice, Inbred BALB C; D009946:Organothiophosphorus Compounds / Q000008:administration & dosage / Q000633:toxicity*; D012701:Serotonin / Q000378:metabolism*; D012999:Soman / Q000633:toxicity
chemical_list: D015102:3,4-Dihydroxyphenylacetic Acid; D002800:Cholinesterase Inhibitors; D002802:Cholinesterases; D004298:Dopamine; D009946:Organothiophosphorus Compounds; D012701:Serotonin; D012999:Soman; C009680:VX-agent